{"parse":{"title":"Final maturation induction","pageid":42716948,"revid":855579274,"text":{"*":"<div class=\"mw-parser-output\"><p><b>Induction of final maturation</b> of <a href=\"/wiki/Oocyte\" title=\"Oocyte\">oocytes</a> is a procedure that is usually performed as part of <a href=\"/wiki/Controlled_ovarian_hyperstimulation\" title=\"Controlled ovarian hyperstimulation\">controlled ovarian hyperstimulation</a> to render the oocytes fully developed and thereby resulting in optimal <a href=\"/wiki/Pregnancy_chance\" class=\"mw-redirect\" title=\"Pregnancy chance\">pregnancy chances</a>. It is basically a replacement for the <a href=\"/wiki/Luteinizing_hormone\" title=\"Luteinizing hormone\">luteinizing hormone</a> (LH) surge whose effects include final maturation in natural <a href=\"/wiki/Menstrual_cycle\" title=\"Menstrual cycle\">menstrual cycles</a>.\n</p><p>The main medications used for induction of final maturation are <a href=\"/wiki/Human_chorionic_gonadotropin\" title=\"Human chorionic gonadotropin\">human chorionic gonadotropin</a> (hCG) and <a href=\"/wiki/GnRH_agonist\" class=\"mw-redirect\" title=\"GnRH agonist\">GnRH agonist</a>. In fresh (rather than <a href=\"/wiki/Oocyte_cryopreservation\" title=\"Oocyte cryopreservation\">frozen</a>) <a href=\"/wiki/Autotransplantation\" title=\"Autotransplantation\">autologous</a> cycles of <a href=\"/wiki/In_vitro_fertilization\" class=\"mw-redirect\" title=\"In vitro fertilization\"><i>in vitro</i> fertilization</a>, final oocyte maturation triggering with GnRH agonist instead of hCG decreases the risk of <a href=\"/wiki/Ovarian_hyperstimulation_syndrome\" title=\"Ovarian hyperstimulation syndrome\">ovarian hyperstimulation syndrome</a> but decreases <a href=\"/wiki/Live_birth_rate\" class=\"mw-redirect\" title=\"Live birth rate\">live birth rate</a>. In cycles followed by <a href=\"/wiki/Oocyte_donation\" class=\"mw-redirect\" title=\"Oocyte donation\">oocyte donation</a>, use of GnRH agonists instead of hCG decreases the risk of ovarian hyperstimulation syndrome with no evidence of a difference in live birth rate.<sup id=\"cite_ref-YoussefVan_der_Veen2014_1-0\" class=\"reference\"><a href=\"#cite_note-YoussefVan_der_Veen2014-1\">&#91;1&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Usage_with_ovulation\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Usage with ovulation</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Usage_with_artificial_oocyte_retrieval\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Usage with artificial oocyte retrieval</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Medications\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Medications</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#HCG_versus_GnRH_agonist\"><span class=\"tocnumber\">3.1</span> <span class=\"toctext\">HCG versus GnRH agonist</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#References\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Usage_with_ovulation\">Usage with ovulation</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Final_maturation_induction&amp;action=edit&amp;section=1\" title=\"Edit section: Usage with ovulation\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Induction of final maturation also initiates the mechanisms that eventually result in <a href=\"/wiki/Ovulation\" title=\"Ovulation\">ovulation</a>, and thereby makes the oocytes destined to undergo ovulation unless artificial <a href=\"/wiki/Oocyte_retrieval\" class=\"mw-redirect\" title=\"Oocyte retrieval\">oocyte retrieval</a> is performed first. Therefore, induction of final maturation is also called <b>triggering oocyte release</b> from the ovary, and the administration of <a href=\"/wiki/Pharmaceutical_drug\" class=\"mw-redirect\" title=\"Pharmaceutical drug\">pharmaceutical drugs</a> to induce final maturation is colloquially called giving a \"trigger shot\", even if the plan is to perform artificial oocyte retrieval before ovulation.<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup>\n</p><p>Administration of a drug to trigger oocyte release without oocyte retrieval results in a predictable time of ovulation, with the interval from drug administration to ovulation depending on the type of drug. This avails for <a href=\"/wiki/Sexual_intercourse\" title=\"Sexual intercourse\">sexual intercourse</a> or <a href=\"/wiki/Intrauterine_insemination\" class=\"mw-redirect\" title=\"Intrauterine insemination\">intrauterine insemination</a> (IUI) to conviently be scheduled at ovulation, the most likely time to achieve pregnancy.<sup id=\"cite_ref-ivf.com_3-0\" class=\"reference\"><a href=\"#cite_note-ivf.com-3\">&#91;3&#93;</a></sup>\n</p><p>In cycles stimulated with <a href=\"/wiki/Clomifene\" title=\"Clomifene\">clomifene</a> for intended conception by sexual intercourse, however, triggering oocyte release has been shown to decrease pregnancy chances compared to frequent monitoring with <a href=\"/wiki/LH_surge\" class=\"mw-redirect\" title=\"LH surge\">LH surge</a> tests.<sup id=\"cite_ref-Committee2013_4-0\" class=\"reference\"><a href=\"#cite_note-Committee2013-4\">&#91;4&#93;</a></sup> Therefore, in such cases, triggering oocyte release is best reserved for women who require IUI and in whom LH monitoring proves difficult or unreliable.<sup id=\"cite_ref-Committee2013_4-1\" class=\"reference\"><a href=\"#cite_note-Committee2013-4\">&#91;4&#93;</a></sup> It may also be used when LH monitoring hasn't shown an LH surge by cycle day 18 (where cycle day 1 is the first day of the preseding menstruation) and there is an <a href=\"/wiki/Ovarian_follicle\" title=\"Ovarian follicle\">ovarian follicle</a> of over 20&#160;mm in size.<sup id=\"cite_ref-McWilliams_5-0\" class=\"reference\"><a href=\"#cite_note-McWilliams-5\">&#91;5&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Usage_with_artificial_oocyte_retrieval\">Usage with artificial oocyte retrieval</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Final_maturation_induction&amp;action=edit&amp;section=2\" title=\"Edit section: Usage with artificial oocyte retrieval\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>In <a href=\"/wiki/In_vitro_fertilization\" class=\"mw-redirect\" title=\"In vitro fertilization\"><i>in vitro</i> fertilization</a> (IVF), induction of final maturation avails for <a href=\"/wiki/Egg_retrieval\" class=\"mw-redirect\" title=\"Egg retrieval\">egg retrieval</a> when the eggs are fully mature.\n</p><p>In IVF, final maturation induction is preceded by <a href=\"/wiki/Controlled_ovarian_hyperstimulation\" title=\"Controlled ovarian hyperstimulation\">controlled ovarian hyperstimulation</a>. It is suggested that there should be a size of <a href=\"/wiki/Ovarian_follicle\" title=\"Ovarian follicle\">ovarian follicles</a> of at least 15&#160;mm, and serum estradiol level of 0.49 nmol/L before commencing final maturation induction. There are better prospects at a follicle size of 18&#160;mm and serum estradiol level of 0.91 nmol/L.<sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Medications\">Medications</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Final_maturation_induction&amp;action=edit&amp;section=3\" title=\"Edit section: Medications\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Medications used for final maturation and/or release of oocytes include:\n</p>\n<ul><li><a href=\"/wiki/Human_chorionic_gonadotropin\" title=\"Human chorionic gonadotropin\">Human chorionic gonadotropin</a> (HCG or hCG) in a low dose, which may be injected after completed ovarian stimulation. Ovulation will occur between 38 and 40 hours after a single HCG injection.<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup> It is also used in <a href=\"/wiki/In_vitro_fertilization\" class=\"mw-redirect\" title=\"In vitro fertilization\"><i>in vitro</i> fertilization</a>, where it makes the follicles perform their final maturation. A <a href=\"/wiki/Transvaginal_oocyte_retrieval\" title=\"Transvaginal oocyte retrieval\">transvaginal oocyte retrieval</a> is then performed at a time usually between 34 and 36 hours after hCG injection, that is, just prior to when the follicles would rupture. HCG injection confers a risk of <a href=\"/wiki/Ovarian_hyperstimulation_syndrome\" title=\"Ovarian hyperstimulation syndrome\">ovarian hyperstimulation syndrome</a>.</li>\n<li><a href=\"/wiki/Recombinant_DNA\" title=\"Recombinant DNA\">Recombinant</a> <a href=\"/wiki/Luteinizing_hormone\" title=\"Luteinizing hormone\">luteinizing hormone</a> (rLH), recombinant HCG (rHCG) and <a href=\"/wiki/Urine\" title=\"Urine\">urine</a>-derived hCG (uHCG) are equally effective in achieving final follicular maturation in IVF with regards to pregnancy rates and risk of ovarian hyperstimulation syndrome.<sup id=\"cite_ref-Farquhar2013_8-0\" class=\"reference\"><a href=\"#cite_note-Farquhar2013-8\">&#91;8&#93;</a></sup> Therefore, urine-derived hCG (uHCG) is regarded as the best choice for final oocyte maturation triggering in IVF due to availability and cost.<sup id=\"cite_ref-Farquhar2013_8-1\" class=\"reference\"><a href=\"#cite_note-Farquhar2013-8\">&#91;8&#93;</a></sup></li>\n<li><a href=\"/wiki/GnRH_agonist\" class=\"mw-redirect\" title=\"GnRH agonist\">GnRH agonist</a>, which necessitates using a <a href=\"/wiki/GnRH_antagonist\" class=\"mw-redirect\" title=\"GnRH antagonist\">GnRH antagonist</a> protocol for <a href=\"/wiki/Controlled_ovarian_hyperstimulation#Suppression_of_spontaneous_ovulation\" title=\"Controlled ovarian hyperstimulation\">suppression of ovulation during ovarian hyperstimulation</a>, because using GnRH agonist for that purpose as well inactivates the axis for which it is intended to work for final maturation induction.</li></ul>\n<h3><span class=\"mw-headline\" id=\"HCG_versus_GnRH_agonist\">HCG versus GnRH agonist</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Final_maturation_induction&amp;action=edit&amp;section=4\" title=\"Edit section: HCG versus GnRH agonist\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Final maturation induction using GnRH agonist results in a substantial decrease in the risk of <a href=\"/wiki/Ovarian_hyperstimulation_syndrome\" title=\"Ovarian hyperstimulation syndrome\">ovarian hyperstimulation syndrome</a> (OHSS). A <a href=\"/wiki/Cochrane_review\" class=\"mw-redirect\" title=\"Cochrane review\">Cochrane review</a> estimated that using GnRH agonist instead of hCG in IVF decreases the risk of mild, moderate or severe OHSS with an <a href=\"/wiki/Odds_ratio\" title=\"Odds ratio\">odds ratio</a> of approximately 0.15. The review estimated that, for a woman with a 5% risk of mild, moderate or severe OHSS with the use of HCG, the risk of OHSS with the use of a GnRH agonist would be between 0 and 2%.<sup id=\"cite_ref-YoussefVan_der_Veen2014_1-1\" class=\"reference\"><a href=\"#cite_note-YoussefVan_der_Veen2014-1\">&#91;1&#93;</a></sup>\n</p><p>However, using GnRH agonist has a lower <a href=\"/wiki/Live_birth_rate\" class=\"mw-redirect\" title=\"Live birth rate\">live birth rate</a> than when using hCG in <a href=\"/wiki/Autotransplantation\" title=\"Autotransplantation\">autologous</a> oocyte transfers (rather than ones using <a href=\"/wiki/Oocyte_donation\" class=\"mw-redirect\" title=\"Oocyte donation\">oocyte donation</a>). A Cochrane review of autologous oocyte transfers estimated that GnRH agonist, compared to hCG, gives an <a href=\"/wiki/Odds_ratio\" title=\"Odds ratio\">odds ratio</a> of pregnancy of approximately 0.47. It estimated that, for a woman with a 31% chance of achieving live birth with the use of hCG, the chance of a live birth with the use of an GnRH agonist would be between 12% and 24%.<sup id=\"cite_ref-YoussefVan_der_Veen2014_1-2\" class=\"reference\"><a href=\"#cite_note-YoussefVan_der_Veen2014-1\">&#91;1&#93;</a></sup> Likewise, using GnRH agonist instead of hCG was associated with a lower ongoing pregnancy rate (pregnancy beyond 12 weeks) than was seen with HCG (odds ratio 0.70) and a higher rate of early (less than 12 weeks) <a href=\"/wiki/Miscarriage\" title=\"Miscarriage\">miscarriage</a> (odds ratio 1.74). However, a higher pregnancy rate when using hCG is only found in those receiving <a href=\"/wiki/Luteal_support\" title=\"Luteal support\">luteal support</a> without <a href=\"/wiki/Luteinizing_hormone\" title=\"Luteinizing hormone\">luteinizing hormone</a> activity (such as <a href=\"/wiki/Progesterone\" title=\"Progesterone\">progesterone</a> or <a href=\"/wiki/Progestin\" title=\"Progestin\">progestin</a>).<sup id=\"cite_ref-YoussefVan_der_Veen2014_1-3\" class=\"reference\"><a href=\"#cite_note-YoussefVan_der_Veen2014-1\">&#91;1&#93;</a></sup>\n</p><p>Final maturation induction using a GnRH agonist is recommended in women with cancer undergoing <a href=\"/wiki/Fertility_preservation\" title=\"Fertility preservation\">fertility preservation</a>, because ovarian hyperstimulation syndrome is associated with an increased risk of arterial thrombotic events such as <a href=\"/wiki/Stroke\" title=\"Stroke\">stroke</a>, <a href=\"/wiki/Myocardial_infarction\" title=\"Myocardial infarction\">myocardial infarction</a> and peripheral <a href=\"/wiki/Arterial_embolism\" title=\"Arterial embolism\">arterial embolism</a>, and this risk can add to an already increased risk caused by the cancer.<sup id=\"cite_ref-SomiglianaPeccatori2014_9-0\" class=\"reference\"><a href=\"#cite_note-SomiglianaPeccatori2014-9\">&#91;9&#93;</a></sup>\n</p><p>Using hCG versus GnRH agonist has no effect on the risk of <a href=\"/wiki/Multiple_pregnancy\" class=\"mw-redirect\" title=\"Multiple pregnancy\">multiple pregnancy</a>.<sup id=\"cite_ref-YoussefVan_der_Veen2014_1-4\" class=\"reference\"><a href=\"#cite_note-YoussefVan_der_Veen2014-1\">&#91;1&#93;</a></sup> Also, no difference has been found between the regimens regarding <a href=\"/wiki/Live_birth_rate\" class=\"mw-redirect\" title=\"Live birth rate\">live birth rate</a> or ongoing <a href=\"/wiki/Pregnancy_rate\" title=\"Pregnancy rate\">pregnancy rate</a> when the controlled ovarian hyperstimulation was followed by <a href=\"/wiki/Oocyte_donation\" class=\"mw-redirect\" title=\"Oocyte donation\">oocyte donation</a>.<sup id=\"cite_ref-YoussefVan_der_Veen2014_1-5\" class=\"reference\"><a href=\"#cite_note-YoussefVan_der_Veen2014-1\">&#91;1&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Final_maturation_induction&amp;action=edit&amp;section=5\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap\"><ol class=\"references\">\n<li id=\"cite_note-YoussefVan_der_Veen2014-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-YoussefVan_der_Veen2014_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-YoussefVan_der_Veen2014_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-YoussefVan_der_Veen2014_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-YoussefVan_der_Veen2014_1-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-YoussefVan_der_Veen2014_1-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-YoussefVan_der_Veen2014_1-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Youssef, Mohamed AFM; Van der Veen, Fulco; Al-Inany, Hesham G; Mochtar, Monique H; Griesinger, Georg; Nagi Mohesen, Mohamed; Aboulfoutouh, Ismail; van Wely, Madelon; Youssef, Mohamed AFM (2014). \"Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology\". <i>Cochrane Database of Systematic Reviews</i> (10): CD008046. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1002/14651858.CD008046.pub4\">10.1002/14651858.CD008046.pub4</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25358904\">25358904</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Gonadotropin-releasing+hormone+agonist+versus+HCG+for+oocyte+triggering+in+antagonist-assisted+reproductive+technology&amp;rft.issue=10&amp;rft.pages=CD008046&amp;rft.date=2014&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD008046.pub4&amp;rft_id=info%3Apmid%2F25358904&amp;rft.aulast=Youssef&amp;rft.aufirst=Mohamed+AFM&amp;rft.au=Van+der+Veen%2C+Fulco&amp;rft.au=Al-Inany%2C+Hesham+G&amp;rft.au=Mochtar%2C+Monique+H&amp;rft.au=Griesinger%2C+Georg&amp;rft.au=Nagi+Mohesen%2C+Mohamed&amp;rft.au=Aboulfoutouh%2C+Ismail&amp;rft.au=van+Wely%2C+Madelon&amp;rft.au=Youssef%2C+Mohamed+AFM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AFinal+maturation+induction\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://infertility.about.com/od/infertilitytreatments/ss/ivf_treatment_5.htm\">About.com</a></span>\n</li>\n<li id=\"cite_note-ivf.com-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-ivf.com_3-0\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.ivf.com/ovind.html\">IVF.com &gt; Ovulation Induction</a> Retrieved on Mars 7, 2010</span>\n</li>\n<li id=\"cite_note-Committee2013-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Committee2013_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Committee2013_4-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Practice Committee of the American Society for Reproductive Medicine (August 2013). \"Use of clomiphene citrate in infertile women: a committee opinion\". <i>Fertil. Steril</i>. <b>100</b> (2): 341\u20138. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.fertnstert.2013.05.033\">10.1016/j.fertnstert.2013.05.033</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/23809505\">23809505</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Fertil.+Steril.&amp;rft.atitle=Use+of+clomiphene+citrate+in+infertile+women%3A+a+committee+opinion&amp;rft.volume=100&amp;rft.issue=2&amp;rft.pages=341-8&amp;rft.date=2013-08&amp;rft_id=info%3Adoi%2F10.1016%2Fj.fertnstert.2013.05.033&amp;rft_id=info%3Apmid%2F23809505&amp;rft.au=Practice+Committee+of+the+American+Society+for+Reproductive+Medicine&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AFinal+maturation+induction\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-McWilliams-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-McWilliams_5-0\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.houstonfertilityspecialist.com/clomid.html\">Clomiphene Citrate, Clomid</a> <a rel=\"nofollow\" class=\"external text\" href=\"https://archive.is/20140510150039/http://www.houstonfertilityspecialist.com/clomid.html\">Archived</a> 2014-05-10 at <a href=\"/wiki/Archive.is\" title=\"Archive.is\">Archive.is</a>. By Robert B. McWilliams. The Center for Reproduction and Women's Health Care, Houston, Texas. Retrieved May 2014</span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://radiopaedia.org/articles/follicular-monitoring\">Follicular monitoring</a> from <a href=\"/wiki/Radiopaedia\" title=\"Radiopaedia\">Radiopaedia</a>. By Dr Praveen Jha et al.</span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.medscape.com/viewarticle/473515\">HCG Injection After Ovulation Induction With Clomiphene Citrate</a> at Medscape. By Peter Kovacs. Posted: 04/23/2004</span>\n</li>\n<li id=\"cite_note-Farquhar2013-8\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Farquhar2013_8-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Farquhar2013_8-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Farquhar, Cindy; Rishworth, Josephine R; Brown, Julie; Nelen, Willianne LDM; Marjoribanks, Jane (2015). \"Assisted reproductive technology: an overview of Cochrane Reviews\". <i>Cochrane Database of Systematic Reviews</i>. <b>7</b>: CD010537. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1002/14651858.CD010537.pub4\">10.1002/14651858.CD010537.pub4</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26174592\">26174592</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cochrane+Database+of+Systematic+Reviews&amp;rft.atitle=Assisted+reproductive+technology%3A+an+overview+of+Cochrane+Reviews&amp;rft.volume=7&amp;rft.pages=CD010537&amp;rft.date=2015&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD010537.pub4&amp;rft_id=info%3Apmid%2F26174592&amp;rft.aulast=Farquhar&amp;rft.aufirst=Cindy&amp;rft.au=Rishworth%2C+Josephine+R&amp;rft.au=Brown%2C+Julie&amp;rft.au=Nelen%2C+Willianne+LDM&amp;rft.au=Marjoribanks%2C+Jane&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AFinal+maturation+induction\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-SomiglianaPeccatori2014-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-SomiglianaPeccatori2014_9-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Somigliana, E.; Peccatori, F. A.; Filippi, F.; Martinelli, F.; Raspagliesi, F.; Martinelli, I. (2014). \"Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation\". <i>Human Reproduction Update</i>. <b>20</b> (6): 944\u2013951. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1093/humupd/dmu035\">10.1093/humupd/dmu035</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/1355-4786\">1355-4786</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25013217\">25013217</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Human+Reproduction+Update&amp;rft.atitle=Risk+of+thrombosis+in+women+with+malignancies+undergoing+ovarian+stimulation+for+fertility+preservation&amp;rft.volume=20&amp;rft.issue=6&amp;rft.pages=944-951&amp;rft.date=2014&amp;rft.issn=1355-4786&amp;rft_id=info%3Apmid%2F25013217&amp;rft_id=info%3Adoi%2F10.1093%2Fhumupd%2Fdmu035&amp;rft.aulast=Somigliana&amp;rft.aufirst=E.&amp;rft.au=Peccatori%2C+F.+A.&amp;rft.au=Filippi%2C+F.&amp;rft.au=Martinelli%2C+F.&amp;rft.au=Raspagliesi%2C+F.&amp;rft.au=Martinelli%2C+I.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AFinal+maturation+induction\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div></div>\n\n<!-- \nNewPP limit report\nParsed by mw1269\nCached time: 20180909151559\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.100 seconds\nReal time usage: 0.129 seconds\nPreprocessor visited node count: 464/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 10282/2097152 bytes\nTemplate argument size: 90/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 10389/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.041/10.000 seconds\nLua memory usage: 2.42 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%   91.872      1 Template:Reflist\n100.00%   91.872      1 -total\n 66.06%   60.694      4 Template:Cite_journal\n 14.38%   13.212      1 Template:Webarchive\n  2.45%    2.247      1 Template:Main_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:42716948-0!canonical and timestamp 20180909151558 and revision id 855579274\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"Webarchive_template_archiveis_links"},{"sortkey":"","*":"Fertility"},{"sortkey":"","*":"Female_genital_procedures"},{"sortkey":"","*":"Fertility_medicine"},{"sortkey":"","*":"Obstetrics"},{"sortkey":"","*":"Human_pregnancy"},{"sortkey":"","*":"Reproduction"}],"links":[{"ns":0,"exists":"","*":"Archive.is"},{"ns":0,"exists":"","*":"Arterial embolism"},{"ns":0,"exists":"","*":"Autotransplantation"},{"ns":0,"exists":"","*":"Clomifene"},{"ns":0,"exists":"","*":"Cochrane review"},{"ns":0,"exists":"","*":"Controlled ovarian hyperstimulation"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Egg retrieval"},{"ns":0,"exists":"","*":"Fertility preservation"},{"ns":0,"exists":"","*":"GnRH agonist"},{"ns":0,"exists":"","*":"GnRH antagonist"},{"ns":0,"exists":"","*":"Human chorionic gonadotropin"},{"ns":0,"exists":"","*":"In vitro fertilization"},{"ns":0,"exists":"","*":"International Standard Serial Number"},{"ns":0,"exists":"","*":"Intrauterine insemination"},{"ns":0,"exists":"","*":"LH surge"},{"ns":0,"exists":"","*":"Live birth rate"},{"ns":0,"exists":"","*":"Luteal support"},{"ns":0,"exists":"","*":"Luteinizing hormone"},{"ns":0,"exists":"","*":"Menstrual cycle"},{"ns":0,"exists":"","*":"Miscarriage"},{"ns":0,"exists":"","*":"Multiple pregnancy"},{"ns":0,"exists":"","*":"Myocardial infarction"},{"ns":0,"exists":"","*":"Odds ratio"},{"ns":0,"exists":"","*":"Oocyte"},{"ns":0,"exists":"","*":"Oocyte cryopreservation"},{"ns":0,"exists":"","*":"Oocyte donation"},{"ns":0,"exists":"","*":"Oocyte retrieval"},{"ns":0,"exists":"","*":"Ovarian follicle"},{"ns":0,"exists":"","*":"Ovarian hyperstimulation syndrome"},{"ns":0,"exists":"","*":"Ovulation"},{"ns":0,"exists":"","*":"Pharmaceutical drug"},{"ns":0,"exists":"","*":"Pregnancy chance"},{"ns":0,"exists":"","*":"Pregnancy rate"},{"ns":0,"exists":"","*":"Progesterone"},{"ns":0,"exists":"","*":"Progestin"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Radiopaedia"},{"ns":0,"exists":"","*":"Recombinant DNA"},{"ns":0,"exists":"","*":"Sexual intercourse"},{"ns":0,"exists":"","*":"Stroke"},{"ns":0,"exists":"","*":"Transvaginal oocyte retrieval"},{"ns":0,"exists":"","*":"Urine"}],"templates":[{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Webarchive"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Webarchive"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Webarchive/data"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":[],"externallinks":["//doi.org/10.1002/14651858.CD008046.pub4","//www.ncbi.nlm.nih.gov/pubmed/25358904","http://infertility.about.com/od/infertilitytreatments/ss/ivf_treatment_5.htm","http://www.ivf.com/ovind.html","//doi.org/10.1016/j.fertnstert.2013.05.033","//www.ncbi.nlm.nih.gov/pubmed/23809505","http://www.houstonfertilityspecialist.com/clomid.html","https://archive.is/20140510150039/http://www.houstonfertilityspecialist.com/clomid.html","http://radiopaedia.org/articles/follicular-monitoring","http://www.medscape.com/viewarticle/473515","//doi.org/10.1002/14651858.CD010537.pub4","//www.ncbi.nlm.nih.gov/pubmed/26174592","//doi.org/10.1093/humupd/dmu035","//www.worldcat.org/issn/1355-4786","//www.ncbi.nlm.nih.gov/pubmed/25013217"],"sections":[{"toclevel":1,"level":"2","line":"Usage with ovulation","number":"1","index":"1","fromtitle":"Final_maturation_induction","byteoffset":1055,"anchor":"Usage_with_ovulation"},{"toclevel":1,"level":"2","line":"Usage with artificial oocyte retrieval","number":"2","index":"2","fromtitle":"Final_maturation_induction","byteoffset":3485,"anchor":"Usage_with_artificial_oocyte_retrieval"},{"toclevel":1,"level":"2","line":"Medications","number":"3","index":"3","fromtitle":"Final_maturation_induction","byteoffset":4193,"anchor":"Medications"},{"toclevel":2,"level":"3","line":"HCG versus GnRH agonist","number":"3.1","index":"4","fromtitle":"Final_maturation_induction","byteoffset":6243,"anchor":"HCG_versus_GnRH_agonist"},{"toclevel":1,"level":"2","line":"References","number":"4","index":"5","fromtitle":"Final_maturation_induction","byteoffset":9608,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Final maturation induction","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q17002162"}]}}